tetrazol-1-yl]methyl]pyridine; BBG, Brilliant Blue G; Bcl2, B-cell lymphoma 2; BzATP, 20(30)-O-(4-Benzoylbenzoyl)adenosine 50-triphosphate; CaMKII: calmodulin-dependent protein kinase II; CAT, catalase; CREB, cAMP response element binding; DUSP2, dual specificity protein phosphatase 2; DUSP6, dual specificity protein phosphatase 6; EGF, Epidermal growth factor; ERK, Extracellular signal regulated protein kinase; ETS, E twenty-six; GSK3, Glycogen synthase kinase 3; H2O2, hydrogen peroxide; HO-1, heme oxygenase-1; IGF-I, Insulin-like growth factor-I; IL6, Interleukin-6; JNKs, c-Jun N-terminal kinase; MAPK, Mitogen-activated protein kinase; MEK, Mitogen extracellular activated kinase; MRS2179, 2′-Deoxy-N6-methyl adenosine 3′,5′-diphosphate;
MRS2211, 2-[(2-Chloro-5-nitrophenyl)azo]-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; NRF2, nuclear factor (erythroid-derived 2)-like 2; PI3K, Phosphatidylinositol 3-kinase; PKA, Protein kinase A; PKC, Protein kinase C; PLC, Phospholipase C; PTP, protein tyrosine phosphatase; SOD, superoxide dismutase; THR, thioredoxin reductase; BDNF, brain-derived neurotrophic factor.
A C C E P T E D M
A N U S C R I P T  P2Y1, P2Y13 and P2X7 receptors display multifaceted neuroprotection in neural cells  Nucleotide receptors counteract oxidative stress through ERK and GSK3 signalling  PTP and DUSP phosphatases are novel nucleotide receptors targets for cell homeostasis  Environmental and temporal milieu set the outcome of nucleotide receptor activation
Highlights:
 Protection against excitotoxicity, oxidative and genotoxic stress is part of the multifaceted neuroprotective role of P2Y1, P2Y13 and P2X7 receptors in astrocytes and neurons.  Activation of ERK and PI3K/Akt/GSK3 cascades by nucleotide receptors underlies the expression of antioxidant genes to counteract oxidative stressinduced cell death.  PTP and DUSP phosphatases are revealed as novel targets for nucleotide receptors to maintain cell homeostasis and fight against oxidative and genotoxic stress.  Different cellular contexts and temporal events in the damaged brain area define the final beneficial or detrimental outcome of nucleotide receptor activation.
Introduction
The technological advances in the last decades have also contributed to progress in the knowledge of the nervous system. However, given its complexity, every single discovery has opened new questions. Although small pieces of the complex puzzle are been identified, the molecular mechanisms that mediate the development, those involved in the maintenance of their structure and function in the adult, and the mechanisms that are altered in aging or pathological processes remain to be elucidated. Purinergic signalling mediated by extracellular nucleotides seems to contribute in all of these events.
Purinergic signalling comprises all the stages from the storage of nucleotides into secretory vesicles by specific vesicular transporters (VNUT) to their subsequent exocytotic release, and the activation of a plethora of nucleotide receptors, both ionotropic (P2X) and metabotropic (P2Y) receptors, and the very diverse intracellular signalling pathways dependent on the cellular type and context. Nucleotides can also be released to the extracellular environment after tissue damage by vesicular-independent mechanisms acting as warning signals to trigger processes for the maintenance of cell survival. In addition, degradation of nucleotides in the extracellular space by ectonucleotidases generates compounds that can activate other nucleotide receptors, making the purinergic signalling a much more complex event than the rest of neurotransmitter systems.
So far, seven P2X subunits (P2X1-P2X7) and eight P2Y (P2Y1,2,4,6,11,12,13,14) receptors have been cloned and characterized according to the pharmacological profile, sequence identity and transduction mechanism (Coddou et al., 2011; von Kugelgen and Hoffmann, 2016) . Whereas P2X receptors are ATP-activated cationic channels, P2Y receptors discriminate between adenine or uridine nucleotides even distinguishing between di-or triphosphate nucleotides. In vitro studies indicate that most of the nucleotide actions involved both ionotropic and metabotropic receptors, which even play opposite effects (Chorna et al., 2004; del Puerto et al., 2012; Jimenez E. et al., 2011; Kucher and Neary, 2005; Rodrigues et al., 2005; Villarejo-Lopez et al., 2017) . Some effects also require the cooperation with other extracellular mediators. Therefore, the final cellular response depends on the integration of the multiple intracellular cascades.
In the present work, we focus on signalling mechanisms triggered by nucleotide receptors, specifically, the ionotropic P2X7 and the metabotropic P2Y1 and P2Y13 receptors, regarding the intracellular routes that explain their neuroprotective roles in certain types of glial and neuronal cells. Many of these signalling cascades are shared with growth factors (EGF and IGF-I) and neurotrophins (BDNF). Not in vain, many signalling proteins can function as crucial convergence points, such as MAP kinases cascades, PI3K/Akt axis, GSK3, as a crossroad for metabolic events, and the Ca 2+ /PLC pathway that connects membrane lipids and calcium signalling. Additionally, other nucleotide receptors could contribute to neuroprotection as they are also relevant in CNS pathophysiology, such as P2X2/P2X3 and P2X4 in pain transmission, and P2Y2, P2Y6 and P2Y12 in neuroinflammation, but they have not been included in the present review, because they will be covered by specialists in other chapters of the present issue.
Presence of P2X7 and ADP receptors in the central nervous system. Among the ionotropic family, P2X7 receptor (P2X7R) is one of the most studied and controversial receptor, due to its atypical pharmacological and structural features: it functions as a homotrimer, requires millimolar ATP concentrations for activation, and exhibits an unusually long intracellular C-terminal domain (Bartlett et al., 2014) . Prolonged stimulation of the P2X7R regulates additional events such as the mitochondrial membrane depolarization, the production of reactive oxygen species (ROS), the formation of plasma membrane pores and plasma membrane blebbing, all of them phenomena that in the end lead to cell death in some situations (Adinolfi et al., 2018; Salas et al., 2013; Surprenant et al., 1996) . For decades, the expression of P2X7R has been considered exclusive for cells from immune lineage, however, it was cloned from a rat brain library, and it is expressed in the nervous system from very early stages, being present in neurons, astroglia and oligodendroglia (Amadio et al., 2002; Carrasquero et al., 2009; Fumagalli et al., 2004; Hervas et al., 2003; Matute et al., 2007; Nobile et al., 2003) . P2X7R mediates multiple actions at the nervous system. Many of them are related to deleterious effect of P2X7R activation in microglia, astrocytes and oligodendrocytes, through its participation in the expression and release of pro-inflammatory mediators, free radicals and excitotoxic molecules that contribute to cell death (Ficker et al., 2014) . In line with this, P2X7R appears to be upregulated in some pathologies including brain ischemia, spinal cord injury, epileptic seizures, Huntington's disease, Alzheimer's disease, multiple sclerosis, and in brain tumors, contributing to neurodegeneration (Adinolfi et al., 2018; Amadio et al., 2017; Bartlett et al., 2014; Diaz-Hernandez et al., 2009; Franke et al., 2004; Matute, 2008; Pedata et al., 2016; Sperlagh and Illes, 2014; Volonte et al., 2016) . In addition, P2X7R also participates in homeostatic functions that are more related to milder activation in neurons and astrocytes, such as neurotransmission, regulation of axonal growth/remodeling and neuroprotection, as described below (Carrasquero et al., 2010; Diaz-Hernandez et al., 2008; Miras-Portugal et al., 2016; .
The presence of P2X7R in neurons has been a matter of intense debate and recently reviewed (Illes et al., 2017; Miras-Portugal et al., 2017) . Plenty of data confirm the detection of P2X7R in glial and neuronal cells through different expression approaches, including in situ hybridization, immunodetection, and electron microscopy (Deuchars et al., 2001; Sperlagh et al., 2002; Wirkner et al., 2005; Yu et al., 2008) . However, in many cases, P2X7R expression was not corroborated by functional responses (Metzger et al., 2017) . And it is still under examination that glial cells present in the preparations are responsible for some P2X7-mediated responses firstly attributed to neurons (Rubini et al., 2014) . This possibility is supported by the controversy in the use of specific antibodies against P2X7 that were not validated in knock-out mice models (Masin et al., 2012; Sanchez-Nogueiro et al., 2005; Sim et al., 2004) . On the other hand, many studies were able to record specific responses in neuronal types that fulfil the P2X7R criteria (Anderson and Nedergaard, 2006) . These studies include electrophysiological recordings, intracellular free calcium determinations, and activation of signaling cascades that occurred in cultured neurons after P2X7R stimulation (Amadio et al., 2002; Carrasquero et al., 2009; Deuchars et al., 2001; Diaz-Hernandez et al., 2008; Hervas et al., 2003; Ortega et al., 2009) . Whether these responses can be reproduced or not in vivo is also under discussion and needs to be further clarified.
ADP-selective receptors comprise the P2Y1, P2Y12 and P2Y13 subtypes and are of remarkable pharmacological importance within the metabotropic nucleotide receptors. P2Y1 was the first P2 receptor cloned, and mainly couples to phospholipase C (PLC) activation and intracellular calcium mobilization. P2Y1 is one of the most abundant P2Y receptors in the brain, being expressed in neurons, astrocytes and oligodendrocytes (Carrasquero et al., 2005; Franke et al., 2004; Jimenez et al., 2000; Schicker et al., 2010) . P2Y12 and P2Y13 receptors were more recently cloned and identified, and they mainly coupled to Gi proteins. Interestingly, P2Y12 receptor turned out to be the target of clopidrogel, an antithrombotic drug widely used for decades without knowing its molecular target (Hollopeter et al., 2001 ). The expression of P2Y12 receptor in the brain appears to be more restricted than other subtypes. P2Y12 receptor is mainly expressed in oligodendrocytes and microglia (Amadio et al., 2006; Quintas et al., 2018; Sasaki et al., 2003) , although its presence in other cells cannot be discarded considering that there are scarce tools available to discriminate between P2Y12 and P2Y13 receptors. Our group was pioneer in the functional characterization of P2Y13 receptors in cells from neural origin, both in primary cultures of granule neurons and astrocytes from rat cerebellum, where we characterized the signalling cascades activated by this receptor obtaining very promising and novel results. We showed that in rat granule neurons P2Y13 receptor couples exclusively via Gi activating the neuronal survival pathway PI3-Kinase/Akt/GSK3, whereas in cerebellar astrocytes it is also able to induce intracellular calcium mobilization (Carrasquero et al., 2009; Ortega et al., 2008) . Both astrocytes and neurons coexpress P2Y13 and P2Y1 receptors, as also seen in platelets with P2Y1 and P2Y12 receptors (Fumagalli et al., 2004; Leon et al., 2003) , and could be explained because the presence of P2Y1 receptor seems to be essential for the expression of the other members of the Gicoupled subfamily, the P2Y12 and P2Y13 subtypes (see recent review ). P2Y1 and P2Y13 receptors, together with P2X7R, regulate axonal growth in hippocampal and cortical neurons (del Puerto et al., 2012) . Astrocytic and neuronal P2Y1 receptors have been involved in the regulation of cerebral blood flow, glutamate neurotransmission, and astrogliosis processes (Domercq et al., 2006) . In relation to this, it has been shown that astroglial P2Y1 and microglial P2Y13 receptors regulate astrogliosis process after traumatic brain injury (Quintas et al., 2018) , where P2Y1 expression is upregulated in astrocytes to induce proliferation and form the glial scar. At the first stages, the recruitment of microglia to the injured zone may reduce astrocyte proliferation, delaying the formation of the astrocytic scar, in order to keep open the path for more immune cells infiltration to resolve inflammation. Once the inflammatory process is over, microglial cells change their phenotype, releasing astrocytes from the proliferative brake, and paving the way for a full tissue remodelling and repairing. The inhibitory action of microglia was mediated by P2Y13 receptors. Other interesting finding recently reported for the microglial P2Y13 is its role as a cleaning system, facilitating cell turnover during the neurogenesis process (Stefani et al., 2018) . P2Y1, P2Y12 and P2Y13 are also involved in the regulation of nociception in the spinal cord (Jimenez E. et al., 2011) . The three ADP-selective receptors are localized on astrocytes and glycinergic interneurons and act in a paracrine way to modulate the activity of glycine transporters. It was elegantly demonstrated that ADP receptor stimulation activates the glial glycine transporter (GLYT1), which may reduce glycine concentration in the surrounding of glutamatergic neurons, decreasing NMDA-depending signalling
and pain transmission. Moreover, ADP receptor stimulation inhibits the neuronal glycine transporter GLYT2, increasing glycinergic neurotransmission that also contributes to pain relief.
P2X7 and ADP receptors could be also molecular targets for neuroprotection. Neuroprotection is the term covering all the strategies, including both pharmacological and physical procedures, which can be useful to recover neuronal functionality and to avoid cell death. In the present review we cover the survival intracellular mechanisms that can be displayed by nucleotide receptors to protect against excitotoxicity and oxidative or genotoxic stress, which represent common events in brain pathologies and in neurodegeneration.
Are P2 receptors targets for neuroprotection in excitotoxicity?
Excitotoxicity represents an active cell death mechanism operating during early stages in stroke, ischemia and traumatic brain injury, being also prevalent in neurodegeneration. After energetic misbalance in stroke onset or following massive cell damage, high levels of extracellular excitatory neurotransmitters are released, such as glutamate and ATP (Pedata et al., 2016) . The over-activation of ionotropic glutamate receptors, including NMDA, AMPA and kainate receptors, together with other sources of ionic imbalance, trigger a cascade of toxic events that result in cellular calcium overload and neuronal death (Moskowitz et al., 2010) . The increase in cytoplasmic calcium concentration has the ability of activate a set of downstream enzymatic activities, among them, phospholipases, proteases and nucleases that will cause loss of cellular integrity. In addition, calcium-dependent mechanisms also alter mitochondrial function, causing mitochondrial depolarization, activation proteins of the apoptotic machinery and other enzymatic activities that generate excessive ROS production. Therefore, neuroprotective strategies against excitotoxic insults can be achieved preventing the full activation of the mitochondrial apoptotic cascade pathway.
As mentioned above, in pathological situations, the ATP released also contributes to excitotoxic response. Growing evidence point to the participation of P2X7R in both ATP release and cell death responses (Arbeloa et al., 2012; Cisneros-Mejorado et al., 2015; Matute et al., 2007; Pellegatti et al., 2005) . In this sense, blocking P2X7R with specific antagonists could be a good strategy to prevent cell death (Wang et al., 2015; Zhao et al., 2016) . For instance, several reports describe the role of P2X7R antagonist BBG to protect against focal cerebral ischemia in animal models, where P2X7R is a critical player in the ischemic neuronal death achieved because of intracellular calcium overload and caspase activation. In this case, phosphorylation of PI3 kinase and ERK is also involved in the apoptotic event, and is prevented by BBG treatment (Caglayan et al., 2017) . P2X7R is also activated in dissociated cultures of rat cortical neurons following oxygen-glucose deprivation (OGD), conditions that mimic ischemia. Moreover, the administration of BBG after proximal middle cerebral artery occlusion (pMCAO) in rats decreased the infarcted area size and attenuated brain damage (Arbeloa et al., 2012) .
Nevertheless, it is necessary to take into account that not always P2X7 blockade can result in protective responses, since the inhibition of these receptors can be detrimental. As a reference, despite the promising results of targeting NMDA and AMPA glutamate receptors to counteract excitotoxicity in animal models of ischemia, they have failed to
improve outcome in stroke patients when translated to clinical trials (Ducruet et al., 2009; Segura et al., 2008) . Because glutamate excitotoxicity takes place at very early stages or even during the acute phase of the ischemic cascade, the administration of NMDA blockers could interfere with the late recovery phase in which NMDA signalling is necessary to mediate neuroplasticity and tissue remodelling (Lo, 2008) . This consideration can be also relevant for nucleotide receptors, since contradictory results have been described in ischemic models.
From this point of view, beneficial effects of nucleotide receptors activation can also take place during the excitotoxic event. In agreement with this, glutamatergic cerebellar neurons provide a suitable model to undertake neuroprotective actions against excitotoxicity. The activation P2Y13 and P2X7 receptors ameliorates apoptotic-induced cell death after exposition to milder concentrations of 100-200 M glutamate (Ortega et al., 2011) . The survival promoting activity elicited by both receptors converged on the same intracellular pathway. They activated transcription factor CREB, a well-known target of ERK signalling in neurons that induces the expression of antiapoptotic proteins of the bcl-2 family (Contestabile, 2002) . Together with nucleotide receptors, BDNF neurotrophin also coupled to CREB phosphorylation and activation to prevent glutamateevoked cell death. Although ERK signalling was enhanced through different transducing mechanisms for BDNF and nucleotide receptors, they seemed to act independently in the neuroprotective effect, being PI3K-dependent in the case of P2Y13 and BDNF receptors, and Ca 2+ /CaMKII-dependent for P2X7R (Ortega et al., 2011) . These findings give evidence of the relevant role of P2Y13 and P2X7 nucleotide receptors maintaining balanced ERK signalling in neurons to support survival (Table 1 ).
The neuroprotective role here reported for P2X7R contrasts to the general view of the original P2X7R cell death, which is found in cells of the immune lineage but also in many peripheral models and neural populations. However, opposite functions have been found for P2X7R in similar cellular models belonging to different species and exposed to different environmental conditions (Miras-Portugal et al., 2016; Sperlagh and Illes, 2014; Volonte et al., 2012) . As an example, whereas P2X7R mediates trophic functions in mouse cortical and rat cerebellar astrocytes (Carrasquero et al., 2009; , the opposite occurs in mouse cerebellar astrocytes, in which brief treatments with the P2X7 agonist, BzATP, mediate the rapid accumulation of propidium iodide and lead to cell death (Salas et al., 2013) . Differences in P2X7 expression levels due to culture conditions or in specific mouse strains must be behind these apparently contradictory results (Amadio et al., 2002; Ohishi et al., 2016) . In neuroblastoma cells, P2X7R covers a dual role exerting a tonic proliferative activity at low concentrations of agonist and behaving as pro-apoptotic receptor at millimolar concentrations of ATP (Adinolfi et al., 2005) . These findings are not surprising since have been also described for NMDA receptors that share great similarities with P2X7R. In cortical neurons, transient and suboptimal NMDAR stimulation triggers survival signalling and elicits neuroprotection (Habas et al., 2006) . Therefore, P2X7 and NMDA receptors must be coupled to specific signalling microdomains under certain conditions that define their death/survival decisions (Ortega et al., 2010) . In addition, it is necessary to point out the variability and heterogeneity that characterize P2X7R. This receptor is highly polymorphic and many genetic variants and polymorphisms can explain its wide variety of functions and its resistance or predisposition to induce cell death (Cheewatrakoolpong et al., 2005; Nicke et al., 2009; Schwarz et al., 2012; Sluyter and Stokes, 2011; Sorge et al., 2012) . Of interest, known functional splice variants of the P2X7 receptor, such as P2X7A and B isoforms, have been associated with proliferation and cancer progression or cytotoxicity (Adinolfi et al., 2010; Giuliani et al., 2014) .
Antioxidative stress mechanisms activated by P2Y1 and P2Y13 nucleotide receptors
Oxidative stress arises when the production of reactive oxygen species (ROS) exceeds the endogenous antioxidant capacity. Enhanced production of ROS and free radicals can derive from the impairment of mitochondrial oxidative phosphorylation and other exogenous sources. Oxidative stress directly leads to apoptotic cell death by direct damage to lipids, proteins and DNA, as well as contributing to the initiation and progression of the inflammatory response characteristic of pathological situations. Neural cell populations are particularly vulnerable to oxidative damage due to the limited antioxidant defense mechanisms. For instance, oxidative stress is a hallmark of neurodegenerative events and the main cause of cell damage after traumatic brain injury and ischemic insults. Considering that P2X7R is upregulated in many of these pathologies, the blockade of this receptor would be a good strategy for recovery (Adinolfi et al., 2018; Amadio et al., 2017; Bartlett et al., 2014; Diaz-Hernandez et al., 2009; Franke et al., 2004; Matute, 2008; Pedata et al., 2016; Sperlagh and Illes, 2014; Volonte et al., 2016) .
On other hand, ATP released during oxidative conditions also functions as a danger signal to initiate defensive cellular response. Accumulating evidence reveals that astrocytes represent one of the first lines of defense in oxidant damaging conditions through the activation of P2Y1 receptors. At least, three different mechanisms displayed by P2Y1 receptors converge to elicit a full neuroprotective response against oxidative stress: i) by directly inducing the expression of a set of genes with antioxidant properties; ii) by counteracting the activation of signalling proteins or cascades that lead to cell death; iii) by promoting the release of diffusible factors that protect surrounding neurons and astrocytes in the brain damaged area (Table 1, Figure 1 ).
In rat forebrain astrocytic cultures, ATP protects against H2O2-induced oxidative stress through PLC activation and increasing intracellular calcium concentration, which confirms the participation of metabotropic P2Y receptors. In addition, the protective effect was fully reversed by the P2Y1 antagonist MRS2179, demonstrating the main contribution of this receptor to promote survival. The onset of cytoprotection requires long time periods (>12h), since involves the novo synthesis of proteins. DNA microarray studies and real-time PCR analysis demonstrate the up-regulation of some types of oxidoreductase genes (thioredoxin and carbonyl reductases and superoxide dismutase-2 like gene) by P2Y1 receptor activation, which depends on ERK signalling. Therefore, the protective role of ATP via P2Y1 receptors against oxidative stress could be explained by the activation of the endogenous astrocytic antioxidative machinery (Shinozaki et al., 2006; Shinozaki et al., 2005) .
In the same line, P2Y1 appears to work together with P2Y11 receptors to elicit neuroprotection in rat newborn astrocytic cultures submitted to milder oxidative stress. In H2O2-challenged astrocytes, protection elicited by 2MeSADP and ATPS agonists correlates well with a decrease in ROS accumulation and stabilization of total antioxidant glutathione (GSH). Coupled signalling to PLC-Ca 2+ and PKA activation contributes to
the expression of several antioxidant genes, such as catalase (CAT), several forms of superoxide dismutase (SOD2, SOD3) and genes involved in GSH synthesis (Forster and Reiser, 2016) .
The second level of protection counteracts the toxic effects of intracellular cascades activated during oxidative stress. Deregulation of MAPK signalling is a common event in oxidative stress and other cytotoxic insults that leads to sustained activation of three types of MAP kinases: ERK, p38 and JNK (Chu et al., 2004; Junttila et al., 2008; Subramaniam and Unsicker, 2010) . Even if MAPKs become over-activated, they can function as a defense mechanism because prolong the expression of antiapoptotic genes. However, they can also turn toxic to the cells, especially when the activated forms of these kinases accumulate into the nucleus for long periods (Stanciu and DeFranco, 2002; Subramaniam et al., 2008; Subramaniam et al., 2005) . Therefore, homeostatic control of MAP kinases activity represents another protective strategy to prevent full activation of transcription factors that can promote cell death. Again, P2Y1 receptors contribute to protection against oxidative stress through the regulation of the intensity and duration of MAP kinase signalling. Exposition to H2O2 in rat forebrain astrocytes mainly activates src-tyrosine kinase that is upstream the persistent activation of ERK1,2 into the nucleus. The protective effect of P2Y1 receptor stimulation hampers the activation of this src-ERK signalling pathway. In fact, MEK1-ERK inhibition protects astrocytes against H2O2-evoked cell death. Studies of gene expression by GeneChip microarray performed in 2MeSADP-stimulated astrocytes demonstrate the up-regulation of protein tyrosine phosphatase (PTP). The increased activity of PTP endorses dephosphorylation and inactivation of src tyrosine kinase and prevents nuclear accumulation of ERK proteins during exposure to H2O2. In addition, P2Y1-induced expression of thioredoxin reductase (TrxR) contributes to increased activity of PTP. These findings indicate that the extent of the protective effect of P2Y1 receptor against H2O2-evoked cell death depends on the ability to restore basal levels of ERK1,2 phosphorylation (Shinozaki et al., 2006) .
One step further in the protective mechanisms displaying by P2Y1 receptors against oxidative damage involves intercellular communication between astrocytes and neurons. In co-cultures of hippocampal astrocytes and neurons, protection against H2O2-induced cell death clearly depends on astrocytic P2Y1 receptor activation, being lost in P2Y1-deficient co-cultures. The cytokine IL-6 was identified as the diffusible factor released in response to astrocytic P2Y1 stimulation, which contributes to cell survival of neighboring neurons. The mechanism of action of IL-6 could involve the novo synthesis of new antioxidant genes (Fujita et al., 2009) (Table 1) .
Although astrocytes behave as essential supporters of neuronal function, under certain conditions neurons can also elicit defensive responses that involve the activation of wellknown survival intracellular pathways. A similar mechanism of protection against H2O2-induced cell damage to that reported in astrocytes occurs in cerebellar neurons, in which 2MeSADP agonist increases survival and prevents the production of ROS. In turn, P2Y13 receptor is responsible of this effect because neuroprotection can be abolished in the presence of selective antagonist MRS2211. The neuroprotective mechanism requires the activation of the signalling cascade PI3K/Akt/GSK3. Akt-mediated GSK3 phosphorylation (in Ser 21,9 residues for -and -isoforms, respectively) inhibits its catalytic activity towards Nrf2, and prevents proteasomal degradation of this transcription (Cuadrado, 2015; Ortega et al., 2008; Rada et al., 2012) . The accumulation of cytoplasmic Nrf2 allows its translocation into the nucleus, where functions as a master regulator of phase-II antioxidative defense genes (Cuadrado et al., 2018; Jazwa and Cuadrado, 2010) . Among them, heme oxygenase-1 (HO-1) expression is increased upon 2MeSADP stimulation. Moreover, 2MeSADP-elicited neuroprotection is abolished in Nrf2-and P2Y13 receptor-deficient neurons. These findings support the notion that the Nrf2/HO-1 antioxidant axis represents a neuroprotective target for P2Y13 receptors in cerebellar neurons (Table 1, Figure 1) (Espada et al., 2010; Ortega et al., 2008) .
Previous data evidence that P2Y1 and P2Y13 nucleotide receptors can be neuroprotective in pathological conditions associated with oxidative damage (hypoxia and ischemia). Trying to translate these promising results to putative therapeutic application, new borano-phosphate adenine nucleotides exhibiting high selectivity for hP2Y1 receptors have been synthesized. The borano-phosphate modification improves pharmacokinetics of these analogs in human serum, and is responsible for the Fe(II) chelation leading to slowdown of Fenton´s reaction. In addition, these compounds retain their ability to function as P2Y1 agonists, promoting neuroprotection against H2O2 challenge in cultured cortical neurons. Thereby, they can be excellent novel candidates as multifunctional drugs with a high neuroprotective profile, combining their potential as antiapoptotic P2Y1 receptor agonists with the Fe(II)-chelation activity and radical scavenging (Azran et al., 2013) .
Role of P2 receptors in genotoxic stress
Directly correlated to oxidative stress, DNA damage or genotoxic stress is also behind many brain pathological events (Madabhushi et al., 2014) . Different elements can converge to elicit genotoxic stress. There is a bidirectional association between oxidative and genotoxic stress. Oxidative conditions contribute to the generation of oxidative DNA adducts, a form of DNA damage caused by covalent attachment of a chemical moiety to DNA that can produce mutations linked to certain diseases and cancers. Other forms of DNA lesions consist of single and double-stranded breaks (SSBs, DSBs) that not only accumulate in senescence, but also after the exposition to certain toxic inputs, such as UV radiation and different cytotoxic chemicals. Under conditions of persistent DNA damage, many aspects of DNA biology can be affected. For instance, transcriptional inhibition can finally promote neurodegeneration, due to deficits in the expression of critical genes required to maintain cell survival. Many genes related to neurotransmission and synaptic function become down-regulated in human aged-brains, which could explain cognitive deficits during ageing and neurodegenerative insults (Loerch et al., 2008; Lu et al., 2004) . In addition, defects in the mechanisms of DNA repair has also been associated with neurodegenerative diseases, including Alzheimer´s and Parkinson´s diseases and ALS, in which oxidative lesions and SSBs have been found (Lillenes et al., 2016) ]. Therefore, counteracting DNA damage and its consequences is essential to elicit a full neuroprotective response.
At the level of signalling pathways, MAPK cascades result mainly affected by DNA damage or genotoxic stress contributing to neuronal dysfunction (Hetman et al., 2010) . The most usual way of MAPK kinase deregulation involves the failure in the deactivation mechanisms by protein phosphatases activities. In the context of genotoxic stress, the A C C E P T E D M A N U S C R I P T function of MAPK phosphatases (MKPs) can be compromised as a result of transcriptional inhibition. This family of phosphatases functions as dual specificity phosphatases, also termed DUSPs, and constitute signalling units with their MAPK substrates. Indeed, they are transcriptionally induced by MAPKs and participate in negative feedback loops to terminate MAPK signalling (Dickinson and Keyse, 2006; Hendriks and Pulido, 2013; Nunes-Xavier et al., 2011; Patterson et al., 2009 ). In addition, DUSPs can become directly inactivated by oxidative damage at the level of key cysteine residue in the catalytic domain (Levinthal and Defranco, 2005) . Subsequently, defective protein phosphatase function, either by transcriptional inhibition or by oxidative stress impairs MAPK dephosphorylation and promotes MAPK long-term activation with their associated detrimental effects in neural cells (Chu et al., 2004) . Consistent with these notions, both DUSP protein phosphatases and MAPKs appear relevant targets for neuroprotection.
The potential protective role of nucleotide receptors in genotoxic stress has been studied in cultured cerebellar neurons and astrocytes treated with chemotherapeutic drugs, such as cisplatin. Cisplatin is an antineoplastic drug that induces the formation of DNA adducts and presents neurotoxic side effects (Gonzalez et al., 2001; Khasabova et al., 2012; Podratz et al., 2011) . Apoptotic-induced cell death by cisplatin is associated with deregulation of MAPK signalling (Brozovic and Osmak, 2007; Gozdz et al., 2008) . When granule neurons are treated with cisplatin at concentrations in the range of that used in chemotherapy, neuronal survival decreases around 40%. Analysis of MAPK signalling reveals increased phosphorylation of ERK and p38 by 2 and 7-fold respectively. Longlasting accumulation of phospho-p38 into the nucleus after cisplatin treatment is responsible for the apoptotic effect of the drug. Remarkably, the increase in phosphorylated p38 levels correlates with a decline in Dusp2 transcript and protein levels. Stimulations with 2MeSADP agonist for 2h prior to cisplatin treatment not only inhibits cell death, but also prevents accumulation of phosphorylated p38 into the nucleus. Gene expression-analysis reveals that DUSP2 phosphatase functions as a transcriptional target of P2Y13 receptors. From these results, DUSP2 can be defined as the nuclear inducible phosphatase responsible for p38 dephosphorylation in cerebellar granule neurons (Morente et al., 2014) (Table 1, Figure 2 ). The neuroprotective role of P2Y13 receptor activation against cisplatin cytotoxicity requires PI3K-dependent ERK signalling (Morente et al., 2014; Perez-Sen et al., 2015) . In addition, DUSP2 could be also responsible for the protection elicited by 2MeSADP against H2O2 and UV treatment in astrocytes, as 2MeSADP prevents ERK overactivation induced by these toxic agents (unpublished results). Overall, these data demonstrate the pivotal role played by P2Y13 receptors in neurons and astrocytes to maintain MAPK signalling homeostasis and cell survival, through feedback cross-regulatory mechanisms implying dual specificity protein phosphatases (Morente et al., 2014; Perez-Sen et al., 2015) .
P2X7R also participates in the defensive response against DNA damage through the regulation of protein phosphatases in cerebellar neurons. Pre-treatment with the P2X7 agonist BzATP increases survival by counteracting caspase-3 activation in response to cisplatin, being these effects prevented with the selective P2X7 antagonist A438079. In this case, the increase in ERK1,2 phosphorylation along cisplatin treatment correlates well with a progressive decline of the ERK-selective phosphatase DUSP6 . In addition, cisplatin exposure also reduces Dusp6 gene transcript levels (unpublished results, Morente, 2013) . These results agree with those described in cortical neurons, where cisplatin-induced DNA damage promotes transcriptional inhibition of DUSP6 phosphatase (Gozdz et al., 2003; Gozdz et al., 2008; Hetman and Gozdz, 2004) . Following this assumption, the protection elicited by P2X7R restores basal levels of ERK activation through DUSP6 induced-expression. These results suggest that the full protection elicited by P2X7R requires ERK signalling as a defence mechanism and intact activity of DUSP6 protein phosphatase.
The complex interplay between ERK and DUSP6 in the neuroprotective mechanism mediated by P2X7R in response to genotoxic stress has also been investigating in a recent work carried out in cerebellar granule neurons and astrocytes (Queipo et al., 2017) . Interestingly, activation of P2X7R regulates DUSP6 expression following a biphasic pattern in both cellular models. The initial phase occurs at short stimulation periods (from 30 min to 1h) with BzATP, and comprises a decrease in DUSP6 cytoplasmic levels due to proteasomal degradation. In a later phase (from 1 to 2h), DUSP6 proteins recover until reaching basal levels in neurons, or even exceeding the basal in astrocytes. In addition, ERK activity is responsible for the regulatory effect of P2X7R on DUSP6 expression. First, proteasomal degradation occurs in an ERK-dependent fashion, specifically by DUSP6 phosphorylation at Ser 197 residue in astrocytes. Second, ERK signalling is required to restore DUSP6 expression by increasing Dusp6 gene transcription. Remarkably, the same DUSP6 regulatory mechanism is reproduced by the epidermal growth factor, EGF, which is more relevant in cerebellar astrocytes. Therefore, the regulation of DUSP6 phosphatase expression provides a mechanism by which P2X7R contributes to homeostatic control of MAPK cascades and shape the outcome of ERK signalling. P2X7R participates in feedforward loops to prolong ERK activation towards its cytoplasmic substrates, and also in negative feedback loops to terminate ERK signalling (Figure 2) (Queipo et al., 2017) .
Neuroprotection in in vitro versus in vivo conditions
As referred in the text different events occurring during degeneration and brain injury cannot be treated independently and work together to elicit cell damage. Oxidative stress is inherent to excitotoxicity, in which calcium overload can affect mitochondrial function to generate reactive species. The same is true for genotoxic stress, since DNA-damaging agents also contribute to support oxidative stress. Therefore, the ability of nucleotide receptors to elicit protection against different apoptotic mechanisms demonstrates their multifunctional neuroprotective profile. So far, astrocytic P2Y1-mediated inhibition of cell death covers protection against the different events occurring in apoptosis individually, excitotoxicity and oxidative stress, through activation of PLC signalling and increase in intracellular calcium concentration. At the level of P2Y13 receptors, transcription of antiapoptotic and antioxidant genes can underlie the full neuroprotective response of P2Y13 receptors in cerebellar neurons (Table 1) . Preliminary results suggest that P2Y13 present in cerebellar astrocytes also protect from genotoxic stress induced by exposition to cytotoxic cisplatin and UV radiation. From these results, it can be deduced that P2Y1,13 receptor agonists could be beneficial for several brain pathologies.
However, in in vivo models of brain injury in which all these events converge in neuronal and glial cells, P2Y1 receptors do not retain their neuroprotective activity, and it is the inhibition of P2Y1 receptor that ameliorates neuronal damage. Several studies have shown
that administration of non-selective P2 antagonists (PPADS and suramin) and the P2Y1-specific (MRS 2179) improves neurological deficits in occlusion models of middle cerebral artery (MCAO) (Carmo et al., 2014; Choo et al., 2013; Kharlamov et al., 2002; Lammer et al., 2011) , although the intracellular mechanism was not investigated. Whether P2Y1 receptor is upregulated in glial cells after brain injury, the glial receptor could be implied (Franke et al., 2006; Franke et al., 2012; Franke et al., 2009 ). In fact, glial P2Y1 receptors participate in inflammatory response and the cognitive deficit after focal cerebral stroke and ischemia in rodent models (Chin et al., 2013; Kuboyama et al., 2011) . Only in mouse ischemic models of photo-thrombolysis, the activation of astrocytic P2Y1 receptor with 2MeSADP resulted neuroprotective, restoring astrocyte mitochondrial metabolism and preventing neuronal loss (Zheng et al., 2013; Zheng et al., 2010) . Taken together these results indicate that P2Y1 receptor could play a dual role in vivo. Considering that P2Y1 receptor is present in astrocytes, neurons and microglia, additional studies to elucidate the role of this receptor in vivo models are required.
Concerning P2Y13 receptors, few data are available about the use of P2Y13 ligands in vivo. Promising results have been obtained outside the nervous system for CT1007900 compound, a newly synthesized P2Y13 agonist that regulates HDL metabolism and protects against atherosclerosis. This compound retains stability and activity after administration by oral gavage in mice (Goffinet et al., 2014; Martinez et al., 2015) . These studies open new possibilities for central administration of P2Y13 ligands. However, demonstrating that P2Y13 receptor is a potential target in brain disorders will be a big challenge.
In a different way, the situation for P2X7R in in vivo models tilts the balance towards the use of P2X7 antagonists to ameliorate brain injury and cell death. Several studies in animal models of ischemia and in different neurodegenerative diseases support the detrimental role of P2X7R over-activation (Sperlagh and Illes, 2014) . However, there are also contradictory results concerning P2X7 gene deletion. In some parkinsonian models, lack of P2X7 function do not ameliorate cell loss of dopaminergic neurons (Hracsko et al., 2011) . In line with this, the final decline in the experimental model of multiple sclerosis is exacerbated in P2X7-knock out mice (Chen and Brosnan, 2006) . Differences in the way P2X7 regulate inflammatory events, together with trophic function assigned for this receptor, account for the beneficial role of P2X7R under certain conditions (Orioli et al., 2017) . In neural in vitro models, such as mechanical stressed cortical astrocytes, PI3K/Akt pathway activation through P2X7R contributes to cell repairing . This signalling pathway also appears to be crucial for the P2X7R present in neuron-like neuroblastoma cells, in which P2X7 regulates cell growth and metabolic activity by activating the PI3K/Akt axis and inhibiting GSK3. The therapeutic interest of P2X7 antagonists is based on the interference with PI3K/Akt/HIF axis and VEGF release, thus preventing tumour progression and angiogenesis (Amoroso et al., 2015) . In addition, milder activation of P2X7R in cerebellar neurons could explain their coupled signalling to survival intracellular cascades (PKC/GSK3, ERK/CREB), which contribute to maintain survival after trophic factor deprivation and excitotoxicity (Ortega et al., 2009; Ortega et al., 2011; Ortega et al., 2010) . Therefore, the protective function described in in vitro conditions suggest a dual role for P2X7R in the balance of cell survival (Amoroso et al., 2015) .
Preserving intracellular signalling cascades for neuroprotection
Another interesting point revealed here is the interplay between different apoptotic events at the level of intracellular signalling pathways. It is therefore not surprising that excitotoxicity, oxidative and genotoxic stress also converge in the deregulation of the same targeted mechanisms. Actually, it has been clear that MAPK signalling is deregulated in all these conditions, promoting long-lasting accumulation of activated forms of the different types of MAP kinases. At first term, an increase in MAPK activation could be beneficial and function as a former defence mechanism to prolong the expression of antiapoptotic genes and initiate the repair response, especially for ERKs. However, depending on the cellular context, it can become detrimental. Persistent nuclear accumulation of MAPKs, especially the stress kinases p38 and JNK, can also increase expression of inflammatory and apoptotic genes, or increase phosphorylation of their cytosolic substrates, activating death pathways or altering cytoskeletal dynamics (Mazanetz and Fischer, 2007; Stein and Johnson, 2002; Subramaniam and Unsicker, 2010) . Otherwise, the final effect of sustained MAPK activation can be dependent on cellular context and the spatio-temporal kinetics of MAPK activation at their specific subcellular compartments (Ebisuya et al., 2005; Murphy and Blenis, 2006) .
Growing evidence suggests that impairment of MAPK signalling is associated to both neurodegenerative diseases and ageing (Zhu et al., 2002) . In agreement with this, overactivated forms of MAPKs were detected in degenerating neurons of animal models of Alzheimer and Parkinson disease (Dagda et al., 2008; Gomez-Santos et al., 2002; Zhu et al., 2002) , and the entire ERK pathway appeared dysregulated in post mortem brain samples of AD and PD patients (Pei et al., 2002; Zhu et al., 2003) . Even in ischemic areas following stroke, elevated levels of phosphorylated ERKs are persistent in the penumbra region as a primary defensive barrier (Slevin et al., 2000) . In addition, ERK activation also persists in the surrounding astroglial cells after brain injury (Carbonell and Mandell, 2003) .
The most common reason of MAPK over-activation in pathological conditions is related to deficient deactivation mechanisms. In this respect, protein phosphatases act as important regulators of the magnitude and duration of MAPK signalling, shaping the final cellular outcome. Specific types of protein phosphatases, such as those belonging to the family of dual specificity protein phosphatases (DUSPs) and other tyrosine phosphatases (PTPs), are submitted to different levels of regulation. It is expected that different apoptotic events can affect their function. The effect of DNA-damaging conditions during genotoxic stress, for example, may alter proper levels of transcription, affecting the turnover of these proteins among many others. In addition, oxidative stress can also inactivate them by direct oxidation of key catalytic residues. As a result, their MAPK substrate activation will be sustained. Therefore, it is important to take into consideration that protein phosphatases deserve special attention when approaching neuroprotective strategies.
The important findings described in this review emphasize the role of DUSPs as new targets for nucleotide receptors to elicit neuroprotection. Therefore, nucleotide receptors take part of signalling units with MAPKs, and participate in homeostatic control of MAPK signalling, ending MAPK actions and allowing the specificity of actions of A C C E P T E D M A N U S C R I P T extracellular mediators. According to this, P2Y1 and P2Y13 receptors provide examples of the induced-expression of protein phosphatases, PTPs and DUSP2 respectively, which prevent nuclear accumulation of MAPK signalling and its deleterious effect, whereas P2X7R operates as a signalling unit together with ERK1,2 and cytosolic DUSP6 proteins to control ERK homeostasis.
Several lines of evidence point to the beneficial role of normalized expression of DUSP phosphatases to maintain survival and ameliorate certain damaging conditions. Restoring DUSPs expression and inactivating MAPKs by cannabinoids is required to induce antinociception in models of peripheral nerve injury (Landry et al., 2012) . In addition, in cancer cells, the balance of DUSPs and MAPK signalling can be important for the final outcome. However, some in vivo models provide examples of the opposite effect. During focal and global ischemia models, increased expression of Dusp6 gene appears to be harmful (Soriano et al., 2000) . The same is true in glutamate-treated rat optic nerves and optic nerves obtained from multiple sclerosis patients, indicating that DUSP6 overexpression can function as a risk factor of multiple sclerosis lesions. In addition, overexpression of DUSP6 gene has been detected in several conditions related to excitotoxicity by AMPA receptor stimulation, and is behind the apoptotic activation of the mitochondrial caspase pathway in oligodendrocytes (Domercq et al., 2011) . Additional evidence of alignment between oxidative and genotoxic stress can be found out of the nervous system. Extracellular release of ATP in response to -irradiation, for example, regulates redox balance in RAW264.7 macrophages. Both increase in ROS production and expression of Trx-1 antioxidant genes depended on purinergic signalling in -irradiated macrophages (Ohshima et al., 2011) .
CONCLUDING REMARKS
We have tried to summarize data concerning the neuroprotective role of some P2Y receptors, the ADP receptors P2Y1 and P2Y13, and P2X7 receptor against some toxic insults: excitotoxicity, oxidative and genotoxic stress. Although a priori these findings seem to be contradictory, all together support the dual role of P2 receptors.
The specific function of a nucleotide receptor can range from cell death to trophic functions. In order to explain these apparent contradictory roles for different versions of the same receptor, the impact of the extracellular milieu deserves special attention. Along these lines, many factors contribute to the final outcome, such as the cellular environment, the density of receptors, the levels of extracellular nucleotides, and the impact of other extracellular mediators or danger signals released in pathological conditions. Actually, the cellular context also defines the precise molecular complexes in which these receptors are integrated and their signalling partners. Elucidating how nucleotide receptors may activate different intracellular routes and the way they recruit or activate specific signalling proteins in different subcellular compartments can help to shape the final cellular outcome. All these points can be also taken into consideration because they give important clues about nucleotide receptor function complexity in different conditions, and can help to fully understand and delineate new therapeutic strategies based on purinergic signalling. Oxidative stress causes damage to lipids, proteins and DNA, and ultimately leads to apoptotic cell death. During oxidative insults, activation of P2Y1 and P2Y13 purinergic receptors elicit neuroprotective responses, like an increase in the expression of antioxidant genes and protein phosphatases, and the release of some signalling molecules, contributing to cell survival. The protection mediated by astrocytic P2Y1 receptors depends on PLC activation, the increase in intracellular calcium concentration and ERK1,2 activation. Astrocytic and neuronal P2Y13 receptors neuroprotective signalling mainly involves both ERKs and PI3K/Akt/GSK3 pathway. These mechanisms are required to induce the expression of antioxidant genes (TrxR, SOD, CAT) and phosphatase genes, also to inhibit excessive and detrimental MAPK activation, and, finally, to release protective diffusible factors to protect the surrounding cells. CREB and Nrf2 are some of the transcription factors mediating these actions. The graph represents data obtained in cultured cells that need to be confirmed in in vivo studies. Table 1 . Summary of intracellular signalling events involved in the neuroprotective functions of P2Y1, P2Y13 and P2X7 receptors in astrocytes (a) and neurons (n).
Bcl2, B-cell lymphoma 2; CaMKII, calcium-calmodulin kinase II; CAT, catalase; CREB, cAMP response element binding; DUSP2, dual specificity protein phosphatase 2; DUSP6, dual specificity protein phosphatase 6; ETS, E twenty-six; GSK3, glycogen synthase kinase 3; H2O2, hydrogen peroxide; HO-1, heme oxygenase-1; IL6, interleukin-6; NRF2, nuclear factor (erythroid-derived 2)-like 2; pERK, phosphor-extracellular signal regulated protein kinase; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PTP, protein tyrosine phosphatase; SOD, superoxide dismutase; TrxR, thioredoxin reductase.
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